Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance

被引:13
|
作者
Long, J. [1 ]
Qu, Tao [2 ]
Pan, X. F. [1 ]
Tang, X. [1 ]
Wan, H. H. [1 ]
Qiu, P. [1 ]
Xu, Yan-Hua [1 ]
机构
[1] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Oncol, Jingzhou, Hubei, Peoples R China
[2] Chinese Acad Med Sci, Dept Oncol, Caner Hosp, Beijing, Peoples R China
关键词
Hepatocellular carcinoma; programmed death 1; programmed death ligand-1; T-CELLS; PATHWAY; PD-1; CANCER; B7-H1;
D O I
10.4103/0973-1482.204850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate the correlation between the expression of programmed death 1 (PD-1) and PD ligand-1 (PD-L1) in hepatocellular carcinoma (HCC) and clinical parameters. Materials and Methods: The study comprised tumor sections from 45 HCC patients treated with curative resection, which were evaluated for PD-1 and PD-L1 protein expression by immunohistochemistry. Results: PD-1 and PD-L1 expression was increased in cancers compared to adjacent normal tissues, with a positive rate of 37.78% (17/45) and 62.22% (28/45), respectively, which was positively correlated with the tumor stage and lymph node metastasis, negatively with postoperative prognosis. PD-1 positivity was most frequently observed in stromal tumor-infiltrating lymphocytes. The number of PD-1 positive lymphocyte was correlated with PD-L1 positive expression. Conclusion: PD-L1 and PD-1 are overexpressed in HCC tissues. PD-L1 expression plays a critical role in the pathogenesis of human HCC, suggesting that it might be used as a new biomarker to predict the disease progression and prognosis.
引用
收藏
页码:S1188 / S1192
页数:5
相关论文
共 50 条
  • [1] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [2] Transarterial chemoembolisation enhances programmed death-1 and programmed death ligand-1 expression in hepatocellular carcinoma
    Montasser, A.
    Beaufrere, A.
    Cauchy, F.
    Soubrane, O.
    Colnot, N.
    Tessiore, S.
    Albuquerque, M.
    Paradis, V.
    [J]. VIRCHOWS ARCHIV, 2019, 475 : S20 - S20
  • [3] Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
    Ito, Nozomi
    Tsujimoto, Hironori
    Horiguchi, Hiroyuki
    Shimazaki, Hideyuki
    Miyazaki, Hiromi
    Saitoh, Daizoh
    Kishi, Yoji
    Ueno, Hideki
    [J]. JOURNAL OF SURGICAL RESEARCH, 2020, 251 : 321 - 328
  • [4] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [5] Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma
    Qu, Yuan
    Wang, Di
    Yang, Lin
    Liu, Hui-Ying
    Cui, Wei
    Che, Yi-Qun
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (01) : 75 - 81
  • [6] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    [J]. UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [7] Clinical significance and therapeutic potential of programmed death 1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Nichiporuk, E.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A. M.
    [J]. ONKOLOGIE, 2008, 31 : 80 - 80
  • [8] Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma
    Chang, Hyeyoon
    Jung, Wonkyung
    Kim, Aeree
    Kim, Han Kyeom
    Kim, Wan Bae
    Kim, Ji Hoon
    Kim, Baek-Hui
    [J]. APMIS, 2017, 125 (08) : 690 - 698
  • [9] Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
    Zhou, Tingting
    Xu, Di
    Tang, Bufu
    Ren, Yanling
    Han, Yiru
    Liang, Gege
    Wang, Jing
    Wang, Ling
    [J]. ANTI-CANCER DRUGS, 2018, 29 (09) : 904 - 910
  • [10] Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges
    Yamashita, Kohei
    Iwatsuki, Masaaki
    Ajani, Jaffer A.
    Baba, Hideo
    [J]. ANNALS OF GASTROENTEROLOGICAL SURGERY, 2020, 4 (04): : 369 - 378